GlobeNewswire

Nyxoah receives FDA approval for full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA)

Share

A picture containing clock, light, drawing  Description automatically generated

PRESS RELEASE

Nyxoah receives FDA approval for full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA)

Mont-Saint-Guibert, Belgium – 9th February 2021 – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces that the Company has received approval by the Food and Drug Administration (FDA) for the Magnetic Resonance Imaging (MRI) conditional labeling for the Genio® neurostimulation-based OSA therapy, currently being evaluated in the DREAM pivotal IDE study.

This revised labeling ensures that patients who receive the Genio® system and those already implanted can now undergo full-body 1.5T and 3T MRI diagnostic scans within approved parameters, and access the benefits of Genio® unique bilateral stimulation therapy.

The DREAM (Dual-sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea) study is an Investigational Device Exemption (IDE) trial designed to support the marketing authorization of the Genio® system in the United States.  This is a multicenter study being conducted worldwide including sites in the United States, Germany, Belgium and Australia.

Olivier Taelman, Chief Executive Officer of Nyxoah, commented: “The approval by the Food and Drug Administration (FDA), received only a week after similar CE mark approval in Europe, confirms again the unique and unparalleled design of our technology. With the prevalence of MRI scans in the United States being one of the highest in the world, we are delighted that Nyxoah will be able to fulfil the currently unmet need for full-body 1.5T and 3T MR conditional labeling. Such an extensive labeling is unique to Nyxoah in the field of neurostimulation-based OSA therapies. Currently other therapies cannot fully address this need due to limitations to 1.5T MRI scans and body areas exclusion. As a company, Nyxoah always puts the patient first and seeks to ensure minimal disruption of their daily life and optimal Quality of Life (QOL).”

Prof. B. Tucker Woodson, MD,added: “As the Principal Investigator for the DREAM pivotal IDE study, I’m really pleased with the FDA approval for full-body 1.5T and 3T MRI compatibility for the Genio® system.  MRI scans are often the preferred diagnostic imaging modality for comorbidities affecting OSA patients. This extensive MRI labeling will be a major benefit for all OSA patients who currently receive the Genio® therapy in the United States as part of the DREAM IDE clinical trial, ensuring that they can undergo MRI scans in full safety.”

- ENDS -

For further information, please contact:

Nyxoah
Milena Venkova, Corporate Communications Manager
milena.venkova@nyxoah.com
+32 490 11 93 57

About Nyxoah

Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a CE-validated, patient-centered, next generation hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk1 and comorbidities including cardiovascular diseases, depression and stroke.
Following the successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio® system received its European CE Mark in 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, the DREAM IDE pivotal study for FDA approval and a post-marketing EliSA study in Europe to confirm the long-term safety and efficacy of the Genio® system.
For more information, please visit www.nyxoah.com.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.





1 Young T. et al: Sleep Disordered Breathing and Mortality: Eighteen-Year Follow-up of the Wisconsin Sleep Cohort, Sleep. 2008 Aug 1; 31(8): 1071–1078.



Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Introducing CorityOne™3.3.2021 19:00:00 CETPress release

Next-generation unified EHS and Quality platform empowers those who transform the way the world works Toronto, March 03, 2021 (GLOBE NEWSWIRE) -- Cority, the leading global enterprise EHS software provider, today announced a groundbreaking next-generation release of its true SaaS platform. CorityOne builds on a heritage of pragmatic innovation and is designed to help EHS and business leaders thrive beyond today to build stronger, more resilient, connected, and sustainable organizations that deliver on the promise of a better tomorrow. Recently recognized as a Leader in the Green Quadrant EHS Software 2021 by independent analyst firm, Verdantix, CorityOne brings together the most comprehensive Environmental, Health, Safety (EHS), and Quality management functionality to a common platform approach, unifying capabilities from acquired assets, including Enviance, and setting a new standard for the digital transformation of EHS and Quality. “It’s time to think differently about the future,” s

Bombardier and Aston Martin Announce Intent to Collaborate and Create the Ultimate Convergence of Performance and Style3.3.2021 18:00:00 CETPress release

Exclusive opportunity for Bombardier business aircraft customers to design their aircraft in collaboration with luxury British automotive manufacturer Initiative complements Bombardier’s established design leadership MONTREAL, March 03, 2021 (GLOBE NEWSWIRE) -- Aston Martin and Bombardier – two iconic brands – have signed a letter of intent to collaborate on custom design services for Bombardier business jets. The collaboration would give customers the opportunity for a truly unique design experience, with the meeting of the top creative minds from the luxury automotive and private jet industries. “Bombardier’s discerning customers have come to expect our products’ signature smooth ride and the company’s no-compromise approach to design, performance and reliability at every level of our portfolio,” said Peter Likoray, Senior Vice President, Sales and Marketing, New Aircraft, Bombardier. “We would be proud to add a new facet to this experience that channels Aston Martin’s distinct aesth

Eurocastle to Release Fourth Quarter 2020 Financial Results on 5 March 20213.3.2021 17:56:51 CETPress release

Contact: Oak Fund Services (Guernsey) Limited Company Administrator Attn: Mark Woodall Tel: +44 1481 723450 Eurocastle to Release Fourth Quarter 2020 Financial Results on 5 March 2021 ­­­ Guernsey, 3 March, 2021 – Eurocastle Investment Limited (“Eurocastle” or the “Company”) today announces that it will release its financial results for the twelve months ended 31 December 2020 on Friday, 5 March 2021 before the market opens. ABOUT EUROCASTLE Eurocastle Investment Limited (the “Company” or “Eurocastle”) is a publicly traded closed-ended investment company with investments focused on Italian performing and non-performing loans, Italian loan servicing platforms and other real estate related assets in Italy. On 18 November 2019, the Company announced a plan to realise the majority of its assets with the aim of accelerating the return of value to shareholders. The Company does not currently intend to seek new investments from the proceeds of the realisation but will continue to support its

SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING3.3.2021 16:20:00 CETPress release

Bid date, 2021-03-05Bid Submission Date2021-03-05Bid times10.30-11.00 (CET/CEST) on the Bid dateOffered Amount50 billion SEKMaximum Permitted Bid Volume12.5 billion SEK from an individual bidderSettlement Date2021-03-09Minimum Permitted Bid Volume10 million SEK per bidFinal Repayment Date2025-03-10Maximum Allocation25 per cent of Offered AmountAllocation TimeNot later than 11.30 (CET/CEST) on the Bid dateRepayment Date2022-03-09Option Repayment Date 12023-03-09Option Repayment Date 22024-03-11Interest rateThe Riksbank´s applicable repo rateAdditional interest rate0.10 per centConfirmation of bids to e-maileol@riksbank.se Stockholm, 2021-03-03 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.

AERION, NETJETS AND FLIGHTSAFETY INTERNATIONAL TO EXPLORE FUTURE GLOBAL MOBILITY SOLUTIONS3.3.2021 16:03:23 CETPress release

Aerion® signs expansive Memorandum of Understanding (MOU) with NetJets and FlightSafety International® (FSI) to shape the future of global mobility NetJets and Aerion to explore exclusive partnership for the global mobility platform, Aerion ConnectTM FSI to support Aerion in establishing a new global Supersonic Training Academy NetJets has obtained purchase rights for 20 AS2® supersonic business jets, extending Aerion’s global order backlog to USD $10 billion+ ahead of 2023 production start Reno, NV & Columbus, OH, March 03, 2021 (GLOBE NEWSWIRE) -- Supersonic aircraft company Aerion, the leader in supersonic technology has forged an expansive collaboration with NetJets, the largest private aviation company in the world, and FlightSafety International, the leader in professional aviation training, — both Berkshire Hathaway companies — to shape the future of global mobility. “At Aerion our vision is to build a future where humanity can travel between any two points on our planet within

AT&T and other leading communications companies join the 25GS-PON Multi-Source Agreement (MSA) Group3.3.2021 15:00:00 CETPress release

The 25G symmetric PON multi-source agreement (25GS-PON MSA) Group is growing rapidly, with the addition of seven new members since it was first announcedAT&T’s commitment to the MSA Group highlights the importance of 25GS-PON to the telecommunications industryTechnology vendors including CommScope, Cortina Access, Feneck, HiLight Semiconductor, Hisense Broadband and Semtech among those fast-tracking 25GS-PON commercialization Industry group brings together major operators along with leading system and component vendors to define and promote next-generation 25GS-PON technology in support of emerging 5G and industrial requirements at cost-effective price targets March 3, 2021 The 25GS-PON MSA Group today announced the addition of seven new member companies including AT&T, CommScope, Cortina Access, Feneck, HiLight Semiconductor, Hisense Broadband and Semtech. These companies, along with the ten founding 25GS-PON MSA members, are enabling a move beyond the limitations of 10 Gb/s next-gene